MEDraysintell newsletter is now available

LOUVAIN-LA-NEUVE, Belgium - Sept. 22, 2015 - PRLog -- Nuclear Medicine, Proton Therapy and Brachytherapy are niche markets which together represents far less than 0.1% of the global health expenditures, but represents some of the most exciting healthcare technologies. There is an increasing interest from investors and industry as new technologies and products are being marketed or under development. Following the release of the most recent expert reports about Proton Therapy, Nuclear Medicine and Brachytherapy, MEDraysintell will publish later this year its new report dedicated to Cyclotrons.

To download the newsletter, please click www.medraysintell.com/News.html

See us at EANM in the Rad4Med.be pavilion booth 177/183/184

About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell was founded in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in nuclear medicine, proton therapy and radiotherapy. We aim to form an international team of experts in the field of medical radiation to provide strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the market – the competitive environment as well as the potential for mergers and acquisitions (M&A) – and technology development. MEDraysintell supports the decision process of manufacturers of radiopharmaceuticals and therapeutic radioisotopes, suppliers of equipment and software and members of the investor community.
www.medraysintell.com